comparemela.com

Latest Breaking News On - Vktx - Page 5 : comparemela.com

William Blair Comments on Viking Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:VKTX)

Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) – Analysts at William Blair lowered their Q1 2024 earnings per share estimates for Viking Therapeutics in a research report issued to clients and investors on Wednesday, February 7th. William Blair analyst A. Hsieh now expects that the biotechnology company will post earnings per share of ($0.27) for […]

Greg-zante
William-blair
Sarah-kathryn-rouan
Therapeutics-company-profile
Nasdaq
Vanguard-group-inc
Therapeutics-inc
Balyasny-asset-management
Maxim-group
Blackrock-inc
Securities-exchange-commission
Viking-therapeutics

Q1 2024 EPS Estimates for Viking Therapeutics, Inc. Lowered by William Blair (NASDAQ:VKTX)

Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) – Stock analysts at William Blair cut their Q1 2024 earnings per share estimates for Viking Therapeutics in a report released on Wednesday, February 7th. William Blair analyst A. Hsieh now forecasts that the biotechnology company will post earnings of ($0.27) per share for the quarter, down from […]

William-blair
Sarah-kathryn-rouan
Greg-zante
Therapeutics-inc
Retirement-group
Wetzel-investment-advisors-inc
Great-west-life-assurance-co
Allspring-global-investments-holdings
Us-bancorp
Nasdaq
Maxim-group
Securities-exchange-commission

Viking Therapeutics (NASDAQ:VKTX) Shares Gap Up on Analyst Upgrade

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) shares gapped up prior to trading on Thursday after StockNews.com upgraded the stock to a sell rating. The stock had previously closed at $24.48, but opened at $25.75. Viking Therapeutics shares last traded at $28.04, with a volume of 1,146,586 shares. A number of other brokerages also […]

Greg-zante
Sarah-kathryn-rouan
Level-four-advisory-services
Therapeutics-inc
Nemes-rush-group
Us-bancorp
Nasdaq
Maxim-group
Corient-private-wealth
Viking-therapeutics
Get-free-report
Director-sarah-kathryn-rouan

Viking Therapeutics (NASDAQ:VKTX) Sets New 12-Month High on Analyst Upgrade

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) shares reached a new 52-week high on Friday after Maxim Group raised their price target on the stock from $35.00 to $50.00. Maxim Group currently has a buy rating on the stock. Viking Therapeutics traded as high as $30.40 and last traded at $29.20, with a volume […]

New-york
United-states
Greg-zante
Maxim-group
Therapeutics-inc
Great-west-life-assurance-co
York-state-common-retirement-fund
Pallas-capital-advisors
Sei-investments-co
Retirement-group
Nasdaq
Viking-therapeutics

Viking Therapeutics, Inc. (NASDAQ:VKTX) Director Sarah Kathryn Rouan Sells 25,000 Shares of Stock

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) Director Sarah Kathryn Rouan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $28.05, for a total transaction of $701,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, […]

New-york
United-states
Sarah-kathryn-rouan
Maxim-group
Therapeutics-inc
Retirement-group
Sei-investments-co
Securities-exchange-commission
York-state-common-retirement-fund
Therapeutics-company-profile
Pallas-capital-advisors
Great-west-life-assurance-co

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.